Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide (SCENESSE) in Xeroderma Pigmentosum C: MED and UV-Induced DNA Damage
2021-003642-20Phase 2Active
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jul 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in xeroderma pigmentosum (XP), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Change in minimal erythema dose (MED). Started Jul 2021; status: active.
02
Drugs
Afamelanotide
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on 2021-003642-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003642-20.